Dr. Firas G. Petros
Claim this profileUniversity of Toledo
Studies Prostate Cancer
Studies Bladder Cancer
4 reported clinical trials
22 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
synaptophysin positive
chromogranin positive
2Bladder Cancer
Affiliated Hospitals
Clinical Trials Firas G. Petros is currently running
CG0070
for Bladder Cancer
This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior BCG therapy which is defined as having persistent or recurrent disease within 12 months (Cohort C) or 6 months (Cohort P) following the completion of adequate BCG therapy for HGUC
Recruiting2 awards Phase 35 criteria
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
More about Firas G. Petros
Clinical Trial Related3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Firas G. Petros has experience with
- CG0070
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Avelumab
- Axitinib
Breakdown of trials Firas G. Petros has run
Prostate Cancer
Bladder Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Firas G. Petros specialize in?
Firas G. Petros focuses on Prostate Cancer and Bladder Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are synaptophysin positive.
Is Firas G. Petros currently recruiting for clinical trials?
Yes, Firas G. Petros is currently recruiting for 3 clinical trials in Toledo Ohio. If you're interested in participating, you should apply.
Are there any treatments that Firas G. Petros has studied deeply?
Yes, Firas G. Petros has studied treatments such as CG0070, Nivolumab, Ipilimumab.
What is the best way to schedule an appointment with Firas G. Petros?
Apply for one of the trials that Firas G. Petros is conducting.
What is the office address of Firas G. Petros?
The office of Firas G. Petros is located at: University of Toledo, Toledo, Ohio 43614 United States. This is the address for their practice at the University of Toledo.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.